The top 100 stock
market authors
selected for publication
market authors
selected for publication
Alnylam Pharmaceuticals Inc. (ALNY) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Alnylam Pharmaceuticals Inc. (ALNY) by latest | most commented
- Bio Medical Stock Sector is Where the Action Is
- More on China Biotech Deals: M&A Numbers Misleading
- Alnylam Wins Another China Patent for siRNA
- FDA, Clinical Trial Calendar Updates: Theravance, Gilead, Teva, Alnylam, ReNeuron
- Trading the Trials and FDA Decision Calendar
- Cubist and Alnylam, An Odd Partnership
- Can MicroRNA Reverse Heart Disease?
- Four Biotechs at Attractive Entry Points
- Even Fatter Yields for Pfizer; M&A Targets in the Sector
- 'When There's Blood in the Streets', Buy Biotech Stocks
- Alnylam and RNAi: The Truth Hurts
- Alnylam Pharmaceuticals: A Falling Star
- My Model Biotech Picks: What's Hot and What's Not
- Investing in miRNA: Beware the Hype, Follow the Money
- Can Takeda (or Roche, or Merck, or...) Afford to Ignore RNAi?
- Wednesday Options Outlook: AIG, LM, RL, XRAY, ALNY, EXPE, MAS, XLF, CSCO
- Alnylam and Takeda Form Alliance In RNAi
- Six Significant Gene Therapy Stocks
- Isis Pharmaceuticals Panic Overdone
- Rosetta Genomics: Mining Genes From Junk (Part II)
- China Biotech in Review: Approvals, Deals and Company News
- Alnylam Signs First Transaction with China Biotech on RNAi Research Products
- Alnylam Stakes Claim to 1st Human Demo of Activity for RNAi Therapy
- 2007 Biotech Performance Review
- PBE: Large Biotech Meets Small Biotech
- RNAi: Seeking a Cure at the Flick of a Switch
- RNA Interference Stocks: Invest At Your Own Risk
- Gaming Rules For Trading Biotech Stocks
- Alnylam Pharmaceuticals Soars on Roche Holding Collaboration
- Biotech Day In Review: CuraGen Gets $155 Million For Gene Sequence Division
- Biotech Day In Review: Amgen Hit with SEC Investigation
- Eye on Alnylam: Silencing the Gene
- Best Stem Cell Plays: Osiris and Aastrom
- Biotech Stocks Review: Amphora Sells Oncology Program to Genentech
- Alnylam, CytRx Gain by Moving into RNAi
- Biotech IPO: Highlights from Rosetta Genomics' F1 Filing
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
David Fry
-
2
Philip Davis
-
3
Bill Gross
-
4
Tyler Durden
-
5
TraderMark
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
